or Try an Advanced Search...

    Technical Analysis for GDTC - CytoMed Therapeutics Limited

    Grade Last Price % Change Price Change
    F 2.16 7.46% 0.15
    GDTC closed up 7.46 percent on Friday, May 31, 2024, on 62 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical GDTC trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    Hammer Candlestick Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Lizard Bullish Bullish Day Trade Setup 0.00%
    Doji - Bearish? Reversal 0.00%
    Doji - Bullish? Reversal 0.00%
    Outside Day Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Narrow Range Bar Range Contraction 7.46%
    Older End-of-Day Signals for GDTC ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support 2 days ago
    10 DMA Support 2 days ago
    50 DMA Support 2 days ago
    Gap Up Closed 2 days ago
    10 DMA Resistance 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GDTC Chart by TradingView
    Basic chart:

    Profile

    CytoMed Therapeutics Limited Description

    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapies Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical

    Is GDTC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 20 CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
    Mar 18 CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
    Mar 4 CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
    Jan 29 Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
    Dec 21 One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year
    Dec 5 CytoMed signs agreements to advance research on allogeneic gamma delta T cell technology
    Dec 5 CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
    See more GDTC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.25
    52 Week Low 1.92
    Average Volume 5,005
    200-Day Moving Average 3.11
    50-Day Moving Average 2.11
    20-Day Moving Average 2.09
    10-Day Moving Average 2.06
    Average True Range 0.10
    RSI (14) 53.92
    ADX 13.72
    +DI 37.88
    -DI 25.81
    Chandelier Exit (Long, 3 ATRs) 2.19
    Chandelier Exit (Short, 3 ATRs) 2.25
    Upper Bollinger Bands 2.21
    Lower Bollinger Band 1.97
    Percent B (%b) 0.78
    BandWidth 11.80
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram 0.0022
    Fundamentals Value
    Market Cap 24.9 Million
    Num Shares 11.5 Million
    EPS -0.28
    Price-to-Earnings (P/E) Ratio -7.71
    Price-to-Sales 50.45
    Price-to-Book 2.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.44
    Resistance 3 (R3) 2.42 2.29 2.40
    Resistance 2 (R2) 2.29 2.22 2.31 2.38
    Resistance 1 (R1) 2.23 2.18 2.16 2.25 2.36
    Pivot Point 2.10 2.10 2.07 2.12 2.10
    Support 1 (S1) 2.04 2.03 1.98 2.07 1.96
    Support 2 (S2) 1.91 1.99 1.93 1.94
    Support 3 (S3) 1.85 1.91 1.92
    Support 4 (S4) 1.88